Rani Therapeutics Holdings Inc（RANI）股票分析RANIRani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rani Therapeutics is a good buy right now due to its recent narrowed financial loss of $8.4 million in Q2 2026, down from $11.2 million a year earlier, indicating improved financial management. Additionally, the stock is currently priced at $0.84, significantly lower than its 52-week high of $3.87, suggesting a potential for recovery. The RSI is at 46.93, indicating that the stock is neither overbought nor oversold, which is favorable for entry. However, the main risk is the company's high debt-to-equity ratio of 490.13%, which could impact financial stability if not managed properly.